Medical - Devices
Compare Stocks
5 / 10Stock Comparison
MYO vs ISRG vs SYK vs MDT vs BSX
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Devices
Medical - Devices
Medical - Devices
MYO vs ISRG vs SYK vs MDT vs BSX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices | Medical - Devices | Medical - Devices |
| Market Cap | $34M | $161.07B | $112.69B | $99.94B | $84.08B |
| Revenue (TTM) | $41M | $10.58B | $25.12B | $35.48B | $20.07B |
| Net Income (TTM) | $-15M | $2.98B | $3.25B | $4.61B | $2.89B |
| Gross Margin | 66.0% | 66.3% | 63.5% | 61.9% | 69.0% |
| Operating Margin | -34.1% | 30.5% | 22.4% | 17.9% | 19.8% |
| Forward P/E | — | 43.8x | 19.6x | 14.1x | 16.7x |
| Total Debt | $19M | $303M | $14.86B | $28.52B | $12.42B |
| Cash & Equiv. | $14M | $3.37B | $4.01B | $2.22B | $2.04B |
MYO vs ISRG vs SYK vs MDT vs BSX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Myomo, Inc. (MYO) | 100 | 23.2 | -76.8% |
| Intuitive Surgical,… (ISRG) | 100 | 234.6 | +134.6% |
| Stryker Corporation (SYK) | 100 | 150.3 | +50.3% |
| Medtronic plc (MDT) | 100 | 79.1 | -20.9% |
| Boston Scientific C… (BSX) | 100 | 148.9 | +48.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MYO vs ISRG vs SYK vs MDT vs BSX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MYO is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 25.7%, EPS growth -131.3%, 3Y rev CAGR 38.1%
- 25.7% revenue growth vs MDT's 3.6%
ISRG ranks third and is worth considering specifically for long-term compounding.
- 5.5% 10Y total return vs SYK's 187.1%
- 28.2% margin vs MYO's -36.7%
SYK is the clearest fit if your priority is valuation efficiency.
- PEG 1.32 vs MDT's 36.00
MDT carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 36 yrs, beta 0.47, yield 3.6%
- Beta 0.47, yield 3.6%, current ratio 1.85x
- Lower P/E (14.1x vs 16.7x)
- 3.6% yield, 36-year raise streak, vs SYK's 1.1%, (3 stocks pay no dividend)
BSX is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.34, Low D/E 50.7%, current ratio 1.62x
- Beta 0.34 vs MYO's 1.63, lower leverage
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 25.7% revenue growth vs MDT's 3.6% | |
| Value | Lower P/E (14.1x vs 16.7x) | |
| Quality / Margins | 28.2% margin vs MYO's -36.7% | |
| Stability / Safety | Beta 0.34 vs MYO's 1.63, lower leverage | |
| Dividends | 3.6% yield, 36-year raise streak, vs SYK's 1.1%, (3 stocks pay no dividend) | |
| Momentum (1Y) | -2.8% vs MYO's -82.0% | |
| Efficiency (ROA) | 175.8% ROA vs MYO's -40.8%, ROIC 6.0% vs -86.1% |
MYO vs ISRG vs SYK vs MDT vs BSX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
MYO vs ISRG vs SYK vs MDT vs BSX — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ISRG leads in 2 of 6 categories
MDT leads 2 • MYO leads 1 • SYK leads 0 • BSX leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT is the larger business by revenue, generating $35.5B annually — 861.1x MYO's $41M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to MYO's -36.7%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $41M | $10.6B | $25.1B | $35.5B | $20.1B |
| EBITDAEarnings before interest/tax | -$13M | $3.8B | $6.3B | $9.4B | $4.7B |
| Net IncomeAfter-tax profit | -$15M | $3.0B | $3.2B | $4.6B | $2.9B |
| Free Cash FlowCash after capex | -$17M | $2.8B | $4.3B | $5.4B | $3.6B |
| Gross MarginGross profit ÷ Revenue | +66.0% | +66.3% | +63.5% | +61.9% | +69.0% |
| Operating MarginEBIT ÷ Revenue | -34.1% | +30.5% | +22.4% | +17.9% | +19.8% |
| Net MarginNet income ÷ Revenue | -36.7% | +28.2% | +12.9% | +13.0% | +14.4% |
| FCF MarginFCF ÷ Revenue | -41.3% | +26.8% | +17.1% | +15.2% | +18.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.9% | +23.0% | +11.4% | +8.8% | +15.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +16.3% | +18.8% | +56.0% | -11.9% | +18.5% |
Valuation Metrics
MDT leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, MDT trades at a 63% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), SYK offers better value at 2.36x vs MDT's 36.00x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $34M | $161.1B | $112.7B | $99.9B | $84.1B |
| Enterprise ValueMkt cap + debt − cash | $39M | $158.0B | $123.5B | $126.2B | $94.5B |
| Trailing P/EPrice ÷ TTM EPS | -2.36x | 57.62x | 35.03x | 21.60x | 29.16x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 43.84x | 19.62x | 14.13x | 16.75x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.65x | 2.36x | 36.00x | — |
| EV / EBITDAEnterprise value multiple | — | 43.62x | 20.31x | 14.32x | 25.30x |
| Price / SalesMarket cap ÷ Revenue | 0.82x | 16.00x | 4.49x | 2.98x | 4.19x |
| Price / BookPrice ÷ Book value/share | 3.20x | 9.17x | 5.02x | 2.08x | 3.46x |
| Price / FCFMarket cap ÷ FCF | — | 64.67x | 26.31x | 19.28x | 22.99x |
Profitability & Efficiency
ISRG leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-115 for MYO. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to MYO's 1.70x. On the Piotroski fundamental quality scale (0–9), BSX scores 7/9 vs MYO's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -114.9% | +16.9% | +15.0% | +9.4% | +12.4% |
| ROA (TTM)Return on assets | -40.8% | +14.8% | +6.9% | +175.8% | +6.9% |
| ROICReturn on invested capital | -86.1% | +15.0% | +11.4% | +6.0% | +8.8% |
| ROCEReturn on capital employed | -46.2% | +16.5% | +13.0% | +7.5% | +11.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 | 6 | 6 | 7 |
| Debt / EquityFinancial leverage | 1.70x | 0.02x | 0.66x | 0.59x | 0.51x |
| Net DebtTotal debt minus cash | $5M | -$3.1B | $10.8B | $26.3B | $10.4B |
| Cash & Equiv.Liquid assets | $14M | $3.4B | $4.0B | $2.2B | $2.0B |
| Total DebtShort + long-term debt | $19M | $303M | $14.9B | $28.5B | $12.4B |
| Interest CoverageEBIT ÷ Interest expense | -8.68x | — | 6.72x | 9.08x | 11.03x |
Total Returns (Dividends Reinvested)
MYO leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $15,873 today (with dividends reinvested), compared to $905 for MYO. Over the past 12 months, MDT leads with a -2.8% total return vs MYO's -82.0%. The 3-year compound annual growth rate (CAGR) favors MYO at 18.8% vs MDT's -1.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -12.0% | -19.3% | -15.2% | -18.1% | -40.3% |
| 1-Year ReturnPast 12 months | -82.0% | -15.4% | -22.5% | -2.8% | -46.0% |
| 3-Year ReturnCumulative with dividends | +67.6% | +49.6% | +5.5% | -4.2% | +6.5% |
| 5-Year ReturnCumulative with dividends | -90.9% | +58.7% | +21.5% | -27.7% | +31.2% |
| 10-Year ReturnCumulative with dividends | -99.6% | +554.2% | +187.1% | +26.5% | +155.5% |
| CAGR (3Y)Annualised 3-year return | +18.8% | +14.4% | +1.8% | -1.4% | +2.1% |
Risk & Volatility
Evenly matched — ISRG and BSX each lead in 1 of 2 comparable metrics.
Risk & Volatility
BSX is the less volatile stock with a 0.34 beta — it tends to amplify market swings less than MYO's 1.63 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ISRG currently trades 75.1% from its 52-week high vs MYO's 17.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.63x | 1.02x | 0.55x | 0.47x | 0.34x |
| 52-Week HighHighest price in past year | $4.87 | $603.88 | $404.87 | $106.33 | $109.50 |
| 52-Week LowLowest price in past year | $0.60 | $427.84 | $289.91 | $77.16 | $54.98 |
| % of 52W HighCurrent price vs 52-week peak | +17.9% | +75.1% | +72.7% | +73.3% | +51.7% |
| RSI (14)Momentum oscillator 0–100 | 56.2 | 42.4 | 24.3 | 27.3 | 33.2 |
| Avg Volume (50D)Average daily shares traded | 320K | 1.8M | 2.1M | 7.8M | 15.5M |
Analyst Outlook
MDT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ISRG as "Buy", SYK as "Buy", MDT as "Buy", BSX as "Buy". Consensus price targets imply 61.4% upside for BSX (target: $91) vs 37.2% for SYK (target: $404). For income investors, MDT offers the higher dividend yield at 3.57% vs SYK's 1.14%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $622.60 | $403.69 | $109.50 | $91.33 |
| # AnalystsCovering analysts | — | 55 | 50 | 49 | 43 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.1% | +3.6% | — |
| Dividend StreakConsecutive years of raises | — | — | 34 | 36 | 0 |
| Dividend / ShareAnnual DPS | — | — | $3.36 | $2.78 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.4% | 0.0% | +3.2% | 0.0% |
ISRG leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MDT leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
MYO vs ISRG vs SYK vs MDT vs BSX: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is MYO or ISRG or SYK or MDT or BSX a better buy right now?
For growth investors, Myomo, Inc.
(MYO) is the stronger pick with 25. 7% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Intuitive Surgical, Inc. (ISRG) a "Buy" — based on 55 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MYO or ISRG or SYK or MDT or BSX?
On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.
6x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 32x versus Medtronic plc's 36. 00x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — MYO or ISRG or SYK or MDT or BSX?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +58. 7%, compared to -90. 9% for Myomo, Inc. (MYO). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus MYO's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MYO or ISRG or SYK or MDT or BSX?
By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.
34β versus Myomo, Inc. 's 1. 63β — meaning MYO is approximately 375% more volatile than BSX relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 170% for Myomo, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — MYO or ISRG or SYK or MDT or BSX?
By revenue growth (latest reported year), Myomo, Inc.
(MYO) is pulling ahead at 25. 7% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: Boston Scientific Corporation grew EPS 55. 2% year-over-year, compared to -131. 3% for Myomo, Inc.. Over a 3-year CAGR, MYO leads at 38. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MYO or ISRG or SYK or MDT or BSX?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus -38. 1% for Myomo, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -35. 2% for MYO. At the gross margin level — before operating expenses — BSX leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MYO or ISRG or SYK or MDT or BSX more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 32x versus Medtronic plc's 36. 00x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Medtronic plc (MDT) trades at 14. 1x forward P/E versus 43. 8x for Intuitive Surgical, Inc. — 29. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BSX: 61. 4% to $91. 33.
08Which pays a better dividend — MYO or ISRG or SYK or MDT or BSX?
In this comparison, MDT (3.
6% yield), SYK (1. 1% yield) pay a dividend. MYO, ISRG, BSX do not pay a meaningful dividend and should not be held primarily for income.
09Is MYO or ISRG or SYK or MDT or BSX better for a retirement portfolio?
For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
55), 1. 1% yield, +187. 1% 10Y return). Myomo, Inc. (MYO) carries a higher beta of 1. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +187. 1%, MYO: -99. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MYO and ISRG and SYK and MDT and BSX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MYO is a small-cap high-growth stock; ISRG is a mid-cap high-growth stock; SYK is a mid-cap quality compounder stock; MDT is a mid-cap income-oriented stock; BSX is a mid-cap high-growth stock. SYK, MDT pay a dividend while MYO, ISRG, BSX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.